Tekmira
Pharmaceuticals Corporation TKMR TKM, a leading developer of
RNA interference (RNAi) therapeutics, disclosed that its motions to dismiss
for lack of standing and to disqualify Alnylam's counsel have been denied in
the patent infringement lawsuit filed on January 17, 2012 by Alnylam
Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. in the U.S. District
Court of Massachusetts, clearing the way for Tekmira to provide the customary
answer to this complaint filed in January 2012.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in